Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arrowhead Pharma
(NQ:
ARWR
)
28.66
+0.47 (+1.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arrowhead Pharma
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
November 30, 2023
Shares of Titan Machinery Inc. (NASDAQ: TITN) moved lower during Thursday’s trading following weak quarterly results.
Via
Benzinga
Recap: Arrowhead Pharma Q4 Earnings
November 29, 2023
Via
Benzinga
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
November 29, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Earnings Outlook For Arrowhead Pharma
November 28, 2023
Via
Benzinga
Analyst Expectations for Arrowhead Pharma's Future
September 19, 2023
Via
Benzinga
Analyst Ratings for Arrowhead Pharma
August 08, 2023
Via
Benzinga
Analyst Expectations for Arrowhead Pharma's Future
July 21, 2023
Via
Benzinga
Earnings Scheduled For November 29, 2023
November 29, 2023
Companies Reporting Before The Bell • CollPlant Biotechnologies (NASDAQ:CLGN) is likely to report quarterly loss at $0.13 per share on revenue of $3.50 million.
Via
Benzinga
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy
November 28, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Expert Ratings for Arrowhead Pharma
June 30, 2023
Via
Benzinga
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results
November 16, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023
November 13, 2023
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference
November 06, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023
November 02, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Johnson & Johnson Offloads Rights For Hepatitis B Candidate To GSK
October 31, 2023
GSK plc (NYSE: GSK) and Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) have
Via
Benzinga
Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences
October 03, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
September 27, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023
September 19, 2023
Via
Benzinga
Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023
September 11, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Cramer Says 'Please Stay Away' From This EV Maker, It 'Should Not Be Public'
September 08, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Norfolk Southern Corporation (NYSE: NSC) is the "cheapest I’ve seen in a very long time,
Via
Benzinga
Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences
September 01, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
August 07, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results
July 24, 2023
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
July 21, 2023
Via
Benzinga
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy
July 17, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 06, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
June 27, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
June 24, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million
June 15, 2023
Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.